Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Galapagos NV

Navigating SG&A Expenses: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Viking Therapeutics, Inc. and Galapagos NV, from 2014 to 2023.

Galapagos NV, a leader in the European biotech scene, has seen its SG&A expenses soar by over 1,000% from 2014 to 2022, peaking in 2022 before a notable decline in 2023. This fluctuation reflects strategic shifts and market adaptations. Meanwhile, Viking Therapeutics, Inc., based in the U.S., experienced a steady increase, with a remarkable 200% rise in 2023 compared to its 2014 figures. This growth trajectory underscores its expanding market presence and operational scaling.

Understanding these trends offers valuable insights into the financial strategies and market positioning of these biotech innovators.